The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis

BACKGROUND: We performed the meta-analysis to evaluate the overall safety of programmed cell death-1 (PD-1) or ligand 1 (PD-L1) inhibitor treatment for lung cancer patients. METHOD: Randomized controlled trials were collected according to the Preferred Reporting Items for Systematic Reviews and Meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Heli, Zhang, Zewen, Feng, Alei, Yang, Xiaowei, Zhang, Shuisheng, Zhao, Yi, Zhu, Qingshan, Mao, Yantao, Liu, Kun, Tian, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709159/
https://www.ncbi.nlm.nih.gov/pubmed/31348245
http://dx.doi.org/10.1097/MD.0000000000016439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709159/
https://www.ncbi.nlm.nih.gov/pubmed/31348245
http://dx.doi.org/10.1097/MD.0000000000016439

Ejemplares similares